Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 14
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Vedolizumab and ART in recent HIV-1 infection unveil the role of α4β7 in reservoir size

  • Jimenez-Leon, Maria Reyes|||0000-0003-2723-319X
  • Gasca-Capote, Carmen|||0000-0002-7211-8599
  • Roca-Oporto, Cristina|||0000-0003-0079-5491
  • Espinosa, Nuria|||0000-0003-2249-2352
  • Sobrino, Salvador
  • Fontillon-Alberdi, Maria|||0000-0003-4031-8067
  • Gao, Ce
  • Roseto, Isabelle
  • Gladkov, Gregory
  • Rivas-Jeremias, Inmaculada
  • Neukam, Karin
  • Sánchez Hernández, José Germán
  • Rigo Bonnin, Raül|||0000-0001-5511-074X
  • Cervera-Barajas, Antonio J.
  • Mesones, Rosario
  • García, Federico
  • Alvarez-Rios, Ana Isabel
  • Bachiller, Sara
  • Vitalle, Joana
  • Perez-Gomez, Alberto
  • Camacho-Sojo, María Inés
  • Gallego, Isabel
  • Brander, Christian|||0000-0002-0548-5778
  • McGowan, Ian
  • Mothe, Beatriz|||0000-0001-9975-407X
  • Viciana, Pompeyo|||0000-0001-5606-0166
  • Yu, Xu
  • Lichterfeld, Mathias
  • López Cortés, Luis Fernando|||0000-0002-3804-3458
  • Ruiz-Mateos, Ezequiel|||0000-0001-6747-7813
BACKGROUND. We evaluated the safety and viral rebound, after analytical treatment interruption (ATI), of vedolizumab and ART in recent HIV-1 infection. We used this model to analyze the effect of α4β7 on the HIV-1 reservoir size. METHODS. Participants started ART with monthly vedolizumab infusions, and ATI was performed at week 24. Biopsies were obtained from ileum and cecum at baseline and week 24. Vedolizumab levels, HIV-1 reservoir, flow cytometry, and cell-sorting and antibody competition experiments were assayed. RESULTS. Vedolizumab was safe and well tolerated. No participant achieved undetectable viremia off ART 24 weeks after ATI. Only a modest effect on the time to achieve more than 1,000 HIV-1 RNA copies/mL and the proportion of participants off ART was observed, being higher in the vedolizumab group compared with historical controls. Just before ATI, α4β7 expression was associated with HIV-1 DNA and RNA in peripheral blood and with PD1 and TIGIT levels. Importantly, a complete blocking of α4β7 was observed on peripheral CD4 T cells but not in gut (ileum and cecum), where α4β7 blockade and vedolizumab levels were inversely associated with HIV-1 DNA. CONCLUSION. Our findings support α4β7 as an important determinant in HIV-1 reservoir size, suggesting the complete α4β7 blockade in tissue as a promising tool for HIV-cure combination strategies. TRIAL REGISTRATION. ClinicalTrials.gov NCT03577782. FUNDING. This work was supported by the Instituto de Salud Carlos III (Fondo Europeo de Desarrollo Regional, "a way to make Europe," research contracts FI17/00186 and FI19/00083 and research projects PI18/01532, PI19/01127, PI22/01796), Conserjería de Economía, Conocimiento, Empresas y Universidad, Junta de Andalucía (research projects P20/00906), the Red Temática de Investigación Cooperativa en SIDA (RD16/0025/0020), and the Spanish National Research Council.
Repisalud
Publicación Artículo científico (JournalArticle)

Comprehensive molecular analysis of immortalization hallmarks in thyroid cancer reveals new prognostic markers.

  • Montero-Conde, Cristina
  • Leandro-García, Luis Javier
  • Martínez-Montes, Ángel M
  • Martínez, Paula
  • Moya, Francisco J
  • Letón, Rocío
  • Gil, Eduardo
  • Martínez-Puente, Natalia
  • Guadalix, Sonsoles
  • Currás-Freixes, Maria
  • García-Tobar, Laura
  • Zafon, Carles
  • Jordà, Mireia
  • Riesco-Eizaguirre, Garcilaso
  • González-García, Patricia
  • Monteagudo, María
  • Torres-Pérez, Rafael
  • Mancikova, Veronika
  • Ruiz-Llorente, Sergio
  • Pérez-Martínez, Manuel
  • Pita, Guillermo
  • Galofré, Juan Carlos
  • Gonzalez-Neira, Anna
  • Cascón, Alberto
  • Rodríguez-Antona, Cristina
  • Megías, Diego
  • Blasco, MA
  • Caleiras, Eduardo
  • Robledo Batanero, Mercedes
  • Rodriguez Perales, Sandra
  • Montero-Conde, Cristina
  • Leandro-García, Luis Javier
  • Martínez-Montes, Ángel M
  • Martínez, Paula
  • Moya, Francisco J
  • Letón, Rocío
  • Gil, Eduardo
  • Martínez-Puente, Natalia
  • Guadalix, Sonsoles
  • Currás-Freixes, Maria
  • García-Tobar, Laura
  • Zafon, Carles
  • Jordà, Mireia
  • Riesco-Eizaguirre, Garcilaso
  • González-García, Patricia
  • Monteagudo, María
  • Torres-Pérez, Rafael
  • Mancikova, Veronika
  • Ruiz-Llorente, Sergio
  • Pérez-Martínez, Manuel
  • Pita, Guillermo
  • Galofré, Juan Carlos
  • Gonzalez-Neira, Anna
  • Cascón, Alberto
  • Rodríguez-Antona, Cristina
  • Megías, Diego
  • Caleiras, Eduardo
Comprehensive molecular studies on tumours are needed to delineate immortalization process steps and identify sensitive prognostic biomarkers in thyroid cancer.
Repisalud
Publicación Artículo científico (JournalArticle)

Overexpression of miR-483-5p is confined to metastases and linked to high circulating levels in patients with metastatic pheochromocytoma/paraganglioma.

  • Castro-Vega, Luis Jaime
  • Calsina, Bruna
  • Burnichon, Nelly
  • Drossart, Tom
  • Martínez-Montes, Ángel M
  • Verkarre, Virginie
  • Amar, Laurence
  • Bertherat, Jérôme
  • Rodríguez-Antona, Cristina
  • Favier, Judith
  • Robledo Batanero, Mercedes
  • Gimenez-Roqueplo, Anne-Paule
Repisalud
Publicación Artículo científico (JournalArticle)

Optimizing Genetic Workup in Pheochromocytoma and Paraganglioma by Integrating Diagnostic and Research Approaches

  • Gieldon, Laura
  • William, Doreen
  • Hackmann, Karl
  • Jahn, Winnie
  • Jahn, Arne
  • Wagner, Johannes
  • Rump, Andreas
  • Bechmann, Nicole
  • Nölting, Svenja
  • Knösel, Thomas
  • Gudziol, Volker
  • Constantinescu, Georgiana
  • Masjkur, Jimmy
  • Beuschlein, Felix
  • Timmers, Henri Jlm
  • Canu, Letizia
  • Pacak, Karel
  • Robledo Mercedes, Mercedes
  • Aust, Daniela
  • Schröck, Evelin
  • Eisenhofer, Graeme
  • Richter, Susan
  • Klink, Barbara
Pheochromocytomas and paragangliomas (PPGL) are rare neuroendocrine tumors with a strong hereditary background and a large genetic heterogeneity. Identification of the underlying genetic cause is crucial for the management of patients and their families as it aids differentiation between hereditary and sporadic cases. To improve diagnostics and clinical management we tailored an enrichment based comprehensive multi-gene next generation sequencing panel applicable to both analyses of tumor tissue and blood samples. We applied this panel to tumor samples and compared its performance to our current routine diagnostic approach. Routine diagnostic sequencing of 11 PPGL susceptibility genes was applied to blood samples of 65 unselected PPGL patients at a single center in Dresden, Germany. Predisposing germline mutations were identified in 19 (29.2%) patients. Analyses of 28 PPGL tumor tissues using the dedicated PPGL panel revealed pathogenic or likely pathogenic variants in known PPGL susceptibility genes in 21 (75%) cases, including mutations in IDH2, ATRX and HRAS. These mutations suggest sporadic tumor development. Our results imply a diagnostic benefit from extended molecular tumor testing of PPGLs and consequent improvement of patient management. The approach is promising for determination of prognostic biomarkers that support therapeutic decision-making.
Repisalud
Publicación Artículo científico (JournalArticle)

CD133 Expression in Medullary Thyroid Cancer Cells Identifies Patients with Poor Prognosis.

  • Cordero-Barreal, Alfonso
  • Caleiras, Eduardo
  • López de Maturana, Evangelina
  • Monteagudo, María
  • Martínez-Montes, Ángel M
  • Letón, Rocío
  • Gil, Eduardo
  • Álvarez-Escolá, Cristina
  • Regojo, Rita M
  • Andía, Víctor
  • Marazuela, Mónica
  • Guadalix, Sonsoles
  • Calatayud, María
  • Robles-Díaz, Luis
  • Aguirre, Miguel
  • Cano, Juana M
  • Díaz, José Ángel
  • Saavedra, Pilar
  • Lamas, Cristina
  • Azriel, Sharona
  • Sastre, Julia
  • Aller, Javier
  • Leandro-García, Luis J
  • Calsina, Bruna
  • Roldán-Romero, Juan María
  • Santos, María
  • Lanillos, Javier
  • Cascon Soriano, Alberto
  • Robledo Batanero, Mercedes
  • Montero-Conde, Cristina
  • Rodriguez Antona, Cristina
The identification of markers able to determine medullary thyroid cancer (MTC) patients at high-risk of disease progression is critical to improve their clinical management and outcome. Previous studies have suggested that expression of the stem cell marker CD133 is associated with MTC aggressiveness.
Repisalud
Publicación Artículo científico (JournalArticle)

Integrative multi-omics analysis identifies a prognostic miRNA signature and a targetable miR-21-3p/TSC2/mTOR axis in metastatic pheochromocytoma/paraganglioma

  • Calsina, Bruna
  • Castro-Vega, Luis Jaime
  • Torres-Pérez, Rafael
  • Inglada Perez, Lucia
  • Currás-Freixes, Maria
  • Roldán-Romero, Juan María
  • Mancikova, Veronika
  • Letón, Rocío
  • Remacha, Laura
  • Santos, María
  • Burnichon, Nelly
  • Lussey-Lepoutre, Charlotte
  • Rapizzi, Elena
  • Graña, Osvaldo
  • Álvarez-Escolá, Cristina
  • de Cubas, Aguirre A
  • Lanillos, Javier
  • Cordero-Barreal, Alfonso
  • Martínez-Montes, Ángel M
  • Bellucci, Alexandre
  • Amar, Laurence
  • Fernandes-Rosa, Fabio Luiz
  • Calatayud, María
  • Aller, Javier
  • Lamas, Cristina
  • Sastre-Marcos, Júlia
  • Canu, Letizia
  • Korpershoek, Esther
  • Timmers, Henri J
  • Lenders, Jacques Wm
  • Beuschlein, Felix
  • Fassnacht-Capeller, Martin
  • Eisenhofer, Graeme
  • Mannelli, Massimo
  • Al-Shahrour, Fatima
  • Favier, Judith
  • Rodriguez Antona, Cristina
  • Cascon Soriano, Alberto
  • Montero-Conde, Cristina
  • Gimenez-Roqueplo, Anne-Paule
  • Robledo Mercedes, Mercedes
Rationale: Pheochromocytomas and paragangliomas (PPGLs) are rare neuroendocrine tumors that present variable outcomes. To date, no effective therapies or reliable prognostic markers are available for patients who develop metastatic PPGL (mPPGL). Our aim was to discover robust prognostic markers validated through in vitro models, and define specific therapeutic options according to tumor genomic features. Methods: We analyzed three PPGL miRNome datasets (n=443), validated candidate markers and assessed them in serum samples (n=36) to find a metastatic miRNA signature. An integrative study of miRNome, transcriptome and proteome was performed to find miRNA targets, which were further characterized in vitro. Results: A signature of six miRNAs (miR-21-3p, miR-183-5p, miR-182-5p, miR-96-5p, miR-551b-3p, and miR-202-5p) was associated with metastatic risk and time to progression. A higher expression of five of these miRNAs was also detected in PPGL patients' liquid biopsies compared with controls. The combined expression of miR-21-3p/miR-183-5p showed the best power to predict metastasis (AUC=0.804, P=4.67·10-18), and was found associated in vitro with pro-metastatic features, such as neuroendocrine-mesenchymal transition phenotype, and increased cell migration rate. A pan-cancer multi-omic integrative study correlated miR-21-3p levels with TSC2 expression, mTOR pathway activation, and a predictive signature for mTOR inhibitor-sensitivity in PPGLs and other cancers. Likewise, we demonstrated in vitro a TSC2 repression and an enhanced rapamycin sensitivity upon miR-21-3p expression. Conclusions: Our findings support the assessment of miR-21-3p/miR-183-5p, in tumors and liquid biopsies, as biomarkers for risk stratification to improve the PPGL patients' management. We propose miR-21-3p to select mPPGL patients who may benefit from mTOR inhibitors.
Repisalud
Publicación Artículo científico (JournalArticle)

Targeting Cyclooxygenase-2 in Pheochromocytoma and Paraganglioma: Focus on Genetic Background

  • Ullrich, Martin
  • Richter, Susan
  • Seifert, Verena
  • Hauser, Sandra
  • Calsina, Bruna
  • Martínez-Montes, Ángel M
  • Ter Laak, Marjolein
  • Ziegler, Christian G
  • Timmers, Henri
  • Eisenhofer, Graeme
  • Robledo Batanero, Mercedes
  • Pietzsch, Jens
Cyclooxygenase 2 (COX-2) is a key enzyme of the tumorigenesis-inflammation interface and can be induced by hypoxia. A pseudohypoxic transcriptional signature characterizes pheochromocytomas and paragangliomas (PPGLs) of the cluster I, mainly represented by tumors with mutations in von Hippel-Lindau (VHL), endothelial PAS domain-containing protein 1 (EPAS1), or succinate dehydrogenase (SDH) subunit genes. The aim of this study was to investigate a possible association between underlying tumor driver mutations and COX-2 in PPGLs. COX-2 gene expression and immunoreactivity were examined in clinical specimens with documented mutations, as well as in spheroids and allografts derived from mouse pheochromocytoma (MPC) cells. COX-2 in vivo imaging was performed in allograft mice. We observed significantly higher COX-2 expression in cluster I, especially in VHL-mutant PPGLs, however, no specific association between COX-2 mRNA levels and a hypoxia-related transcriptional signature was found. COX-2 immunoreactivity was present in about 60% of clinical specimens as well as in MPC spheroids and allografts. A selective COX-2 tracer specifically accumulated in MPC allografts. This study demonstrates that, although pseudohypoxia is not the major determinant for high COX-2 levels in PPGLs, COX-2 is a relevant molecular target. This potentially allows for employing selective COX-2 inhibitors as targeted chemotherapeutic agents and radiosensitizers. Moreover, available models are suitable for preclinical testing of these treatments.
Repisalud
Publicación Artículo científico (JournalArticle)

Pheochromocytomas and Paragangliomas: Bypassing Cellular Respiration

  • Cascon Soriano, Alberto
  • Remacha, Laura
  • Calsina, Bruna
  • Robledo Mercedes, Mercedes
Abstract: Pheochromocytomas and paragangliomas (PPGL) are rare neuroendocrine tumors that show the highest heritability of all human neoplasms and represent a paradoxical example of genetic heterogeneity. Amongst the elevated number of genes involved in the hereditary predisposition to the disease (at least nineteen) there are eleven tricarboxylic acid (TCA) cycle-related genes, some of which are also involved in the development of congenital recessive neurological disorders and other cancers such as cutaneous and uterine leiomyomas, gastrointestinal tumors and renal cancer. Somatic or germline mutation of genes encoding enzymes catalyzing pivotal steps of the TCA cycle not only disrupts cellular respiration, but also causes severe alterations in mitochondrial metabolite pools. These latter alterations lead to aberrant accumulation of "oncometabolites" that, in the end, may lead to deregulation of the metabolic adaptation of cells to hypoxia, inhibition of the DNA repair processes and overall pathological changes in gene expression. In this review, we will address the TCA cycle mutations leading to the development of PPGL, and we will discuss the relevance of these mutations for the transformation of neural crest-derived cells and potential therapeutic approaches based on the emerging knowledge of underlying molecular alterations.
Repisalud
Publicación Artículo científico (JournalArticle)

International initiative for a curated variant database improving the diagnosis of hereditary paraganglioma and pheochromocytoma.

  • Ben Aim, Laurene
  • Maher, Eamonn R
  • Cascon Soriano, Alberto
  • Barlier, Anne
  • Giraud, Sophie
  • Ercolino, Tonino
  • Pigny, Pascal
  • Clifton-Bligh, Roderick J
  • Mirebeau-Prunier, Delphine
  • Mohamed, Amira
  • Favier, Judith
  • Gimenez-Roqueplo, Anne-Paule
  • Schiavi, Francesca
  • Toledo, Rodrigo A
  • Dahia, Patricia L
  • Robledo Batanero, Mercedes
  • Bayley, Jean Pierre
  • Burnichon, Nelly
is one of the major genes predisposing to paraganglioma/pheochromocytoma (PPGL). Identifying pathogenic variants in patients with PPGL is essential to the management of patients and relatives due to the increased risk of recurrences, metastases and the emergence of non-PPGL tumours. In this context, the 'NGS and PPGL (NGSnPPGL) Study Group' initiated an international effort to collect, annotate and classify variants and to provide an accurate, expert-curated and freely available variant database.
Repisalud
Publicación Artículo científico (JournalArticle)

Genomic and immune landscape Of metastatic pheochromocytoma and paraganglioma.

  • Calsina, Bruna
  • Piñeiro-Yáñez, Elena
  • Martínez-Montes, Ángel M
  • Caleiras, Eduardo
  • Fernández-Sanromán, Ángel
  • Monteagudo, María
  • Torres-Pérez, Rafael
  • Fustero-Torre, Coral
  • Pulgarín-Alfaro, Marta
  • Gil, Eduardo
  • Letón, Rocío
  • Jiménez, Scherezade
  • García-Martín, Santiago
  • Martin, Maria Carmen
  • Roldán-Romero, Juan María
  • Lanillos, Javier
  • Mellid, Sara
  • Santos, María
  • Díaz-Talavera, Alberto
  • Rubio, Ángeles
  • González, Patricia
  • Hernando, Barbara
  • Bechmann, Nicole
  • Dona, Margo
  • Calatayud, María
  • Guadalix, Sonsoles
  • Álvarez-Escolá, Cristina
  • Regojo, Rita M
  • Aller, Javier
  • Del Olmo-Garcia, Maria Isabel
  • López-Fernández, Adrià
  • Fliedner, Stephanie M J
  • Rapizzi, Elena
  • Fassnacht, Martin
  • Beuschlein, Felix
  • Quinkler, Marcus
  • Toledo, Rodrigo A
  • Mannelli, Massimo
  • Timmers, Henri J
  • Eisenhofer, Graeme
  • Rodriguez Perales, Sandra
  • Domínguez, Orlando
  • Macintyre, Geoffrey
  • Currás-Freixes, Maria
  • Rodríguez-Antona, Cristina
  • Cascón, Alberto
  • Leandro-García, Luis J
  • Roncador, Giovanna
  • García-García, Juan Fernando
  • Pacak, Karel
  • Al-Shahrour, Fatima
  • Robledo Batanero, Mercedes
The mechanisms triggering metastasis in pheochromocytoma/paraganglioma are unknown, hindering therapeutic options for patients with metastatic tumors (mPPGL). Herein we show by genomic profiling of a large cohort of mPPGLs that high mutational load, microsatellite instability and somatic copy-number alteration burden are associated with ATRX/TERT alterations and are suitable prognostic markers. Transcriptomic analysis defines the signaling networks involved in the acquisition of metastatic competence and establishes a gene signature related to mPPGLs, highlighting CDK1 as an additional mPPGL marker. Immunogenomics accompanied by immunohistochemistry identifies a heterogeneous ecosystem at the tumor microenvironment level, linked to the genomic subtype and tumor behavior. Specifically, we define a general immunosuppressive microenvironment in mPPGLs, the exception being PD-L1 expressing MAML3-related tumors. Our study reveals canonical markers for risk of metastasis, and suggests the usefulness of including immune parameters in clinical management for PPGL prognostication and identification of patients who might benefit from immunotherapy.
Repisalud
Publicación Artículo científico (JournalArticle)

Novel Germline Variant in a Patient with Multiple Paragangliomas and Papillary Thyroid Carcinoma.

  • Mellid, Sara
  • Coloma, Javier
  • Calsina, Bruna
  • Monteagudo, María
  • Roldán-Romero, Juan M
  • Santos, María
  • Leandro-García, Luis J
  • Lanillos, Javier
  • Martínez-Montes, Ángel M
  • Rodríguez-Antona, Cristina
  • Montero-Conde, Cristina
  • Martínez-López, Joaquín
  • Ayala, Rosa
  • Matias-Guiu, Xavier
  • Robledo Batanero, Mercedes
  • Cascón, Alberto
Over the past few years, next generation technologies have been applied to unravel the genetics of rare inherited diseases, facilitating the discovery of new susceptibility genes. We recently found germline gain-of-function variants in two patients with head and neck paragangliomas causing a characteristic hypermethylated DNA profile. Here, whole-exome sequencing identifies a novel germline variant (p.Gly332Arg) in a patient with bilateral carotid paragangliomas, papillary thyroid carcinoma and idiopathic intellectual disability. The variant, located in the Pro-Trp-Trp-Pro (PWWP) domain of the protein involved in chromatin targeting, affects a residue mutated in papillary thyroid tumors and located between the two residues found mutated in microcephalic dwarfism patients. Structural modelling of the variant in the DNMT3A PWWP domain predicts that the interaction with H3K36me3 will be altered. An increased methylation of target genes, compatible with a gain-of-function effect of the alteration, was observed in saliva DNA from the proband and in one independent acute myeloid leukemia sample carrying the same p.Gly332Arg variant. Although further studies are needed to support a causal role of variants in paraganglioma, the description of a new alteration in a patient with multiple clinical features suggests a heterogeneous phenotypic spectrum related to germline variants.
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publicación Artículo científico (JournalArticle)

Association of miR-126-3p, miR-1260b and miR-374a-5p with the incidence of heart failure in a population-based cohort: the Hortega Follow-Up Study

  • Grau-Perez, Maria
  • Martinez-Arroyo, Olga
  • Rubia-Martinez, Marta
  • Flores-Chova, Ana
  • Rodríguez-Hernández, Zulema
  • Fernández-Navarro, Pablo
  • Gonzalez-Neira, Anna
  • Alonso, María Rosario
  • Pita, Guillermo
  • Pineda, Silvia
  • Martin-Escudero, Juan C.
  • Redon, Josep
  • Tellez-Plaza, Maria
  • Cortes, Raquel
  • Guasque Ortega, Ana|||0000-0002-2900-8466
[EN] Background: Circulating microRNAs (miRNAs) are emerging markers for cardiovascular prevention and control. miRNAs associated to vascular damage are candidates to play a causal role in the microvascular dysfunction of heart failure (HF). The aim was to evaluate the observational and causal (Mendelian randomization) association of miRNAs related with vascular alterations (miR-126-3p, miR-1260b and miR-374a-5p) with HF incidence in a sample from the general population. Methods: Plasma miRNAs levels were measured in 985 Hortega Study participants using real time quantitative polymerase chain reaction (RT-qPCR). Single nucleotide polymorphisms (SNPs) were genotyped with the TOPMED imputable Illumina GSA array. We identified genetic instrumental variables for miR-126-3p (33 SNPs), miR-1260b (22 SNPs) and miR-374a-5p (35 SNPs) and run several Mendelian randomization approaches. Results: The hazard ratio (95 % confidence interval) of HF by a 10-fold increase in miR-126-3p, miR-1260b and miR-374a-5p was 1.53 (1.09, 2.14), 1.38 (1.03, 1.86), and1.30 (1.09, 1.57), respectively. The corresponding rate differences were 9.7 (-0.1, 19.5), 12.0 (0.4, 23.6) and 9.1 (1.2, 17.1) per 10000 person-years. In flexible dose-response analysis, increased miRNAs levels were associated with higher HF risk, both in the relative and additive scale. In Mendelian randomization analysis, consistently suggestive positive causal associations were found with HF for increased miR-126-3p and miR-1260b levels, but not for miR-374a-5p. Conclusions: In observational analysis, miR-126-3p, miR-1260b and miR-374a-5p levels were positively associ-ated with HF incidence. Mendelian randomization analysis supported a causal role for miR-126-3p and miR-1260b, thus suggesting a potential use as prognostic and therapeutic targets for HF prevention and control., We thank Nuria Alvarez y Belen Herraez, from the Human Genotyping-CEGEN Unit, at the National Center for Cancer Research from the Carlos III Health Institutes, in Madrid (Spain) , for their contribution in the genotyping procedure. This research was funded by health sciences research grants from the Carlos III Health Institute (grant numbers PI19/01796 to J.R.; PI21/00249 and CP22/00069 to R.C.; PI23/01179 to A.O.; FI20/00096 to O.M.-A; and FI22/00032 to A.F.-C.; PI15/00071 and PI22CIII/00029 to M.T.-P.) . This work was also sup-ported by the State Agency for Research (PID2019-108973RB-C21 to M. T.-P.) . Grant IJC2020-045308-I, Juan de la Cierva Incorporacion funded by MCIN/AEI/10.13039/501100011033 and by ESF-Investing in Your Future (to A.O.) ; CNS2022-136175, Research Consolidation Grants, funded by MCIN/AEI/10.13039/501100011033 and European Union "Next Generation EU"/PRTR" (to R.C) .; FP7-HEALTH 11 (grant number no 278249) . It was co-funded by the European Union (the European Regional Development Fund (ERDF) and the European Social Fund (FSE) ) ; CIBER of Obesity and Nutrition Physiopathology (CIBEROBN) (grant numbers CIBER-02-08-2009, CB06/03 and CB12/03/30016) . CIBER of Cardiovascular diseases (CIBERCV) (grant number CB16/11/00261) . CIBEROBN and CIBERCV are co-funded with European Funds for Regional Development (FEDER) , and IDIFEDER/2021/072, CIAICO/2022/181 and INVEST/2023/180 from the Generalitat Valenciana of Spain. Z.R.-H. received a fellowship associated to a Spain National Investigation Agency project (PRE2020-093926) . The genotyping service was carried out at the Genotyping Unit-CEGEN in the Spanish Na-tional Cancer Research Centre (CNIO) , supported by Instituto de Salud Carlos III (ISCIII) , Ministerio de Ciencia e Innovacion. CEGEN is part of the initiative IMPaCT GEN oMICA (IMP/00009) cofunded by ISCIII and the European Regional Development Fund (ERDF)
RUC. Repositorio da Universidade da Coruña
Publicación Artículo científico (JournalArticle)

Individual Telomere Length Decay in Patients With Spondyloarthritis

  • Tamayo, María
  • Pértega-Díaz, Sonia
  • Mosquera Rey, Alejandro
  • Rodríguez, Montserrat
  • Blanco García, Francisco J
  • Fernández-Sueiro, José Luis
  • Gosálvez, Jaime
  • Fernández, José Luis
Clinical trial, [Abstract] Telomere length was sequentially determined in peripheral blood leukocytes (PBL) from patients with ankylosing spondylitis (AS; n = 44) and psoriatic arthritis (PsA; n = 42) followed through 2.93 ± 0.99 years, using a quantitative PCR (qPCR) assay. The initial telomere size from PsA patients was higher than those with cutaneous psoriasis only (n = 53), possibly due to the inflammatory condition. The qPCR assay was sensitive enough to evidence a significant telomere length shortening in PBL from practically all subjects and PsA patients showed a higher rate of loss of telomere sequence than patients with AS during the follow-up time., This study was supported by a grant from the Fondo de Investigaciones Sanitarias (FIS) PI11/01796.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Persistent elite controllers as the key model to identify permanent HIV remission

  • Gasca-Capote, Carmen
  • Ruiz-Mateos, Ezequiel
[Purpose of review] To summarize the heterogeneity in the elite controllers population with the aim to identify a compatible profile with a persistent HIV remission, making distinction between persistent elite controllers, people with HIV (PWHIV) who permanently maintain virological control in the absence of antiretroviral treatment (ART), and transient elite controllers, PWHIV who eventually lose virological control. For this purpose, it is important to consider the mechanisms and biomarkers that have previously been associated with the maintenance and loss of the natural virological control., [Recent findings] Transient elite controllers, before losing virological control, exhibit a distinct metabolomic, proteomic, microRNAs (miRNA), immunological and virological profile compared to persistent elite controllers. In addition to a reduced and less polyfunctional HIV-specific T-cell response, transient elite controllers show a greater proportion of intact proviruses integrated into genic regions. In contrast, persistent elite controllers display a privileged HIV-1 reservoir profile with absence of detected intact proviruses or low proportion of clonal intact proviruses preferentially integrated into genomic features associated with HIV-1 transcriptional repression., [Summary] According to previous studies, the comprehensive characterization of persistent elite controllers might be crucial to identify other PWHIV with this distinct profile as spontaneously cured., This work was supported by the Instituto de Salud Carlos III (Fondo Europeo de Desarrollo Regional, FEDER, “a way to make Europe”, research contracts FI19/00083 and MV20/00057 to C.G.C. and research projects PI19/01127 and PI22/01796 to E.R.M.) and Gilead Fellowships (GLD22/00147 to E.R.M.). E.R.M. was granted by the Spanish National Research Council (CSIC)., Peer reviewed